Potrero Medical raised $4.8 million in a new round of equity financing, according to an SEC filing posted this week.
San Francisco-based Potrero developed the Accuryn monitoring system designed to use urinary catheters as diagnostic tools. The system uses a urinary catheter to deliver real-time, actionable data on urine output, core temperature and intra-abdominal pressure, the company said.
Money in the round came from 14 anonymous investors, according to the SEC filing, with the company looking to raise another $7.2 million before closing the round. Potrero has not yet said how it plans on using funds raised in the round.
In April, Potrero Medical said it won FDA 510(k) clearance for the Accuryn system.
The company said it is engaged in a multicenter randomized clinical study of Accuryn to detect sepsis and critical illness, which is slated to enroll 100 patients in the U.S.
In February, Potrero Medical said the National Institutes of Health are sponsoring the Prescient study of the Accuryn system. The company said it received $2.25 million in Small Business Innovation Research grants from the NIH’s National Institute of General Medical Sciences to run the study.
